Navigation Links
Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), announced today that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA).

Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with its lead product ATPace. This trial is aimed at demonstrating clinical safety and efficacy of ATPace in treating paroxysmal supraventricular tachycardia, or PSVT, in emergency room patients. Upon successful completion of the trial, Duska intends to file a New Drug Application under section 505(b)(2).

The SPA is a process that provides for an official FDA evaluation of Phase 3 clinical study protocols. Once the SPA is agreed to by both the FDA and the trial sponsor, the SPA provides the sponsor with a binding written agreement that the design and analysis of the studies are adequate to support a license application submission if the study is performed according to the SPA and if the results are successful. The SPA agreement may only be changed by the sponsor company or the FDA by a written agreement, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety.

PSVT, one of the most common cardiac arrhythmias, is a rapid, regular heart rate originating in the atria. There are approximately 570,000 persons with PSVT in the United States alone, with an estimated 89,000 new cases diagnosed each year. Patients with PSVT may report palpitations, pounding in the chest, chest pressure or pain, weakness, shortness of breath, or dizziness. The heart rate in PSVT can range from 150-250 beats per minute.

ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intraven
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
4. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
5. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
6. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
7. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
10. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
11. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11
... Australia, March 12, 2007: Progen Industries Limited,(ASX: PGL; NASDAQ: ... liver cancer data has been accepted for late breaking ... the Liver,(EASL). Progen will also be presenting the results ... Cancer Research (AACR),Annual Meeting 2007. , ,In expectation ...
... - Tyrima Demonstrates Good Safety Profile and Excellent,Pharmacokinetic ... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a clinical stage ... the central,nervous system, today announced top-line results from ... candidate for the treatment,of depression and anxiety. In ...
Cached Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2PI-88 Data to be Presented at Key International Conferences 3CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3
(Date:7/25/2014)... 2014 Reproductive Science Center (RSC) of ... Kerri Luzzo, Lead Physician at RSC Rhode Island, received ... accomplishments in fertility care and community outreach issued by ... Annual PBN Awards ceremony held July 24th at Salve ... most highly regarded, emerging leaders in their field were ...
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... regarding all the latest information from the FDA on ... on July 21, that one lot of Ibuprofen and one ... recalled due to mislabeled packaging. Oxcarbazepine is used ... with epilepsy. , The reason for the recall ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3
... to rid the brain of the amyloid buildup that plagues ... the method outlined in a paper published online August 12 ... Center show how the bodys natural way of ridding the ... disease. Then the team demonstrated an experimental method in mice ...
... 2007 UT Southwestern Medical Center researchers have discovered ... the human cardiovascular system, including lowering the elevated heart ... ,We have found that cocaines effects on the ... a drug called dexmedetomidine, which is currently approved by ...
... Food and Drug Administration (FDA) Nanotechnology Task Force is ... effort to tackle the new scientific and regulatory challenges ... clear and candid in acknowledging the pervasive potential of ... pharmaceuticals and devices to cosmetics and food supplements— and ...
... drug that stimulates the growth of infection-fighting white blood ... a chemotherapy-related complication characterized by fever and low white ... by researchers from the University of Rochester School of ... Center. , "Chemotherapy drugs target cancer cells, but ...
... scientists said Monday that they have further evidence to suggest ... would make a promising target for new drugs to ... first identified the enzyme, protein kinase G (PknG), as a ... time, they said that the protein is the secret weapon ...
... created from an egg matured in a laboratory, frozen, thawed ... a medical conference on Monday. ,The baby ... disease, and three other women in the 20-person trial group ... ,Doctors already collect and store eggs from women who face ...
Cached Medicine News:Health News:Draining away brain's toxic protein to stop Alzheimer's 2Health News:Draining away brain's toxic protein to stop Alzheimer's 3Health News:New treatment effective in counteracting cocaine-induced symptoms 2Health News:White Blood Cell Booster May Help Cancer Patients Avoid Deadly Complications 2Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 2Health News:Infertility Breakthrough With First Birth from Lab-matured Egg 3
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Inquire...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
Medicine Products: